Welcome to our dedicated page for Cannabis Bioscience International Holdings SEC filings (Ticker: CBIH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking clinical breakthroughs is hard when Cannabis Bioscience International Holdings Inc (CBIH) scatters trial data, patent counts, and cannabis-related regulatory updates across hundreds of SEC pages. Miss one Form 4 and you could overlook when a lead researcher adds shares ahead of a positive study readout.
Stock Titan solves the problem. Our AI reads every filing the second it hits EDGAR—whether it’s a CBIH quarterly earnings report 10-Q filing packed with R&D spending details or an 8-K on a DEA reclassification hearing—and produces plain-English briefs you can act on. Looking for Cannabis Bioscience International Holdings insider trading Form 4 transactions? We deliver real-time alerts and context so you know why executives moved.
- 10-K annual report: Explore pipeline timelines and risk factors with the Cannabis Bioscience International Holdings annual report 10-K simplified by AI.
- 10-Q: Compare quarter-over-quarter R&D outlays through our Cannabis Bioscience International Holdings earnings report filing analysis.
- Form 4: Track Cannabis Bioscience International Holdings Form 4 insider transactions real-time and spot sentiment shifts.
- 8-K: Get Cannabis Bioscience International Holdings 8-K material events explained—from patent wins to FDA feedback.
- DEF 14A proxy: Review Cannabis Bioscience International Holdings proxy statement executive compensation without digging through tables.
Need quick clarity? Type a natural question like “understanding Cannabis Bioscience International Holdings SEC documents with AI” and jump straight to the summary you need. From Cannabis Bioscience International Holdings executive stock transactions Form 4 to scientific milestone disclosures, every document is translated into insights, saving you hours and sharpening your decisions.
Cannabis Bioscience International Holdings (CBIH) filed a Notification of Late Filing (Form 12b-25) for its Form 10-Q for the period ended August 31, 2025, citing that the financial information for the quarter could not be analyzed and completed on a timely basis.
The company provided preliminary estimates indicating a smaller loss from operations of approximately $66,000 versus $97,604 a year earlier. Estimated revenue is about $36,000 compared with $178,887, and estimated gross profit is about $28,000 versus $170,525 for the prior-year quarter. Estimated total operating expenses are approximately $94,000, down from $268,129, reflecting substantial decreases in general and administrative expenses, professional fees, share-based compensation, and rent. Estimated net loss is about $42,511, compared with $76,305 in the prior year.
Cannabis Bioscience International Holdings, Inc. (CBIH) reported operations across three segments: clinical research (Alpha Research Institute), education and publishing (Pharmacology University) and planned CBD product sales (VitaCookies). For the year ended May 31, 2025, the company recorded revenues of $262,916 and cost of revenues of $203,242, producing operating loss of $421,365 and a reported net loss of $548,820. The company used $329,627 in operating cash flows, had a working capital deficit of $916,878, and an accumulated deficit of $5,882,901. It disclosed concentration risk with 91% of gross revenue from a small number of customers in 2025.
The company disclosed multiple debt arrangements, several in default or arrears, EIDL loans outstanding (~$249,500 noncurrent portion), related-party financing (Jones Note ~$340,855), and convertible-note features on some financings. Management highlighted going concern indicators and weaknesses in controls and board oversight, including no independent directors or audit committee. The filing lists numerous patent applications and product concepts, plus equity issuances raising $244,250 in 2025 from private stock sales.
FAQ
What is the current stock price of Cannabis Bioscience International Holdings (CBIH)?
What is the market cap of Cannabis Bioscience International Holdings (CBIH)?
